A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Latest Information Update: 21 Jun 2022
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms IMmotion150
- Sponsors Roche
- 16 May 2022 Samples from COMPARZ and IMmotion 150 assessing the relation between FOLH1 expression and angiogenesis, as well as clinical outcomes presented at the 117th Annual Meeting of the American Urological Association
- 10 Apr 2021 Results of retrospectively constructed and validated Multi-Omics Responder Scores in multiple public cohorts presented at the 112th Annual Meeting of the American Association for Cancer Research
- 31 Mar 2020 Results evaluating patient-reported outcome published in the BJU International